Fixed-Dose Pain Tablet Combining Pregabalin Celecoxib and B Vitamins

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is no existing technology that provides a stable, immediate-release, fixed-dose combination of pregabalin, celecoxib, and B vitamins (cyanocobalamin, pyridoxine, and thiamine) in the same dosage unit for the treatment of chronic neuropathic and nociceptive pain.

Innovation Solution

A fixed-dose combination pharmaceutical composition of cyanocobalamin, pyridoxine, thiamine, pregabalin, and celecoxib with specific doses and pharmaceutically acceptable carriers, formulated into a single solid, stable, immediate-release pharmaceutical form, such as tablets, to treat chronic pain effectively.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of operation

If a fixed-dose combination of pregabalin, celecoxib, and B vitamins is formulated in a single dosage unit, then treatment convenience and compliance are improved, but formulation stability and manufacturing complexity worsen

Engineering Contradiction:

Improvetreatment convenienceVSAvoidformulation complexity

Core Design Contradiction:

Ease of operationVSDevice complexity

Solution Approach 1:

The patent combines multiple active ingredients (pregabalin, celecoxib, cyanocobalamin, pyridoxine, and thiamine) with different physicochemical properties into a single fixed-dose combination tablet. This merging approach improves treatment convenience by eliminating the need for multiple separate medications while maintaining the synergistic therapeutic effects of all components.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The formulation employs different excipients and manufacturing conditions optimized for each specific active ingredient's properties. This includes using appropriate binders, fillers, and coating materials that are compatible with each drug's stability requirements, thereby managing the formulation complexity through localized optimization rather than a uniform approach.

Inventive Principle:

Principle #3Local quality

2Speed

If immediate-release formulation is used for rapid pain relief, then onset of action is improved, but duration of action and stability worsen

Engineering Contradiction:

Improveonset of actionVSAvoidduration of action

Core Design Contradiction:

SpeedVSDuration of action of stationary object

Solution Approach 1:

The immediate-release formulation is designed to provide rapid onset of action for acute pain relief, while the fixed-dose combination enables periodic administration throughout the day. This periodic dosing strategy maintains therapeutic levels of all active ingredients over time, effectively addressing both the need for rapid relief and sustained duration of action.

Inventive Principle:

Principle #19Periodic action

Data Source

PatentUS20250114390A1Multi-active tablet in the treatment and control of severe chronic pain and method of preparation

Publication Date: 2025.04.10 LAB SILANES S A DE

AI summary

The present disclosure describe a simple optimized method that allows the combined manufacture of five active substances: cyanocobalamin, pyridoxine, thiamine, pregabalin and celecoxib in a single solid, stable, immediate release pharmaceutical form for pain. The combined use of drugs that act at distinct levels is associated with greater pain relief and, as they can be used at lower doses, with a reduced risk of adverse effects. In this context, the combined use of B vitamins plus pregabalin and celecoxib would be associated with greater analgesic activity through complementary action mechanisms.